Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 11Phase 3 8Phase 1/2 7Phase NA 2Phase EARLY_PHASE1 2Phase 4 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C, Chronic 1Carcinoma, Hepatocellular 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 31Bupivacaine 31Vincristine 27Propofol 25Methotrexate 25Cisplatin 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Bevacizumab 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Idarubicin 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × OTHER × Introns × Clear all
NCT00375661 2015-09-02

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Kyoto University Hospital

Phase 4 Completed
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡